![]()
|
|
||||||||
J Biol Chem, Vol. 274, Issue 32, 22502-22507, August 6, 1999
From the Carbamoyl phosphate synthetase (CPS) from
Escherichia coli catalyzes the formation of carbamoyl
phosphate, which is subsequently employed in both the pyrimidine and
arginine biosynthetic pathways. The reaction mechanism is known to
proceed through at least three highly reactive intermediates: ammonia,
carboxyphosphate, and carbamate. In keeping with the fact that the
product of CPS is utilized in two competing metabolic pathways, the
enzyme is highly regulated by a variety of effector molecules including
potassium and ornithine, which function as activators, and UMP, which
acts as an inhibitor. IMP is also known to bind to CPS but the actual effect of this ligand on the activity of the enzyme is dependent upon
both temperature and assay conditions. Here we describe the three-dimensional architecture of CPS with bound IMP determined and
refined to 2.1 Å resolution. The nucleotide is situated at the
C-terminal portion of a five-stranded parallel Carbamoyl phosphate synthetase
(CPS)1 is one of the few
allosterically regulated enzymes whose three-dimensional structure is
now known to high resolution (1, 2). A list of other regulated
proteins, whose molecular architectures are known in quite extensive
detail, includes phosphofructokinase (3), aspartate transcarbamoylase
(4), glutamine synthetase (5), and glycogen phosphorylase (6), among
others. The biochemical role of CPS is to catalyze the formation of
carbamoyl phosphate, an unstable precursor that initiates subsequent
steps in the biosynthesis of both pyrimidine nucleotides and arginine.
The end-product of the pyrimidine biosynthetic pathway, UMP,
allosterically inhibits this enzyme. Conversely, ornithine,
the co-substrate with carbamoyl phosphate in the next step of the
arginine biosynthetic pathway, enhances the catalytic
activity of CPS. Each of these effectors primarily, but not
exclusively, modulates the activity of CPS by raising or lowering the
dissociation constant for Mg2+ATP by approximately one
order of magnitude (7, 8).
As isolated from E. coli, CPS is a large multidomain
heterodimeric protein. The smaller of the two subunits has a molecular weight of ~42,000 and is catalytically responsible for the hydrolysis of glutamine and the subsequent translocation of the ammonia product to
the large subunit (9). The larger subunit (molecular weight ~118,000)
is composed of four major regions as indicated in Fig. 1 (1, 10). Two of these structural units,
known as the carboxyphosphate (Met1-Glu403) and
carbamoyl phosphate (Asn554-Asn936) synthetic
components are homologous to one another and contain all of the
catalytic machinery necessary for the final assembly of carbamoyl
phosphate. These two synthetase units are linked together by a third
domain (Val404- Ala553) whose functional role
in the structure and catalytic properties of CPS is still not well
understood. However, this region of the protein appears to play a role
in the oligomerization of the The binding site for the positive allosteric effector, ornithine, was
identified in the original x-ray structural analysis of CPS (1, 2).
Ornithine was found to straddle the interface between the allosteric
domain and the carbamoyl phosphate synthetic component. Specifically,
the
The Binding of Inosine Monophosphate to Escherichia
coli Carbamoyl Phosphate Synthetase*
,
, and
¶
Department of Biochemistry, College of
Agricultural and Life Sciences, University of Wisconsin, Madison,
Madison, Wisconsin 53705 and the § Department of Chemistry,
Texas A&M University, College Station, Texas 77843
![]()
ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS AND DISCUSSION
REFERENCES
-sheet in the
allosteric domain formed by Ser937 to Lys1073.
Those amino acid side chains responsible for anchoring the nucleotide to the polypeptide chain include Lys954,
Thr974, Thr977, Lys993,
Asn1015, and Thr1017. A series of hydrogen
bonds connect the IMP-binding pocket to the active site of the large
subunit known to function in the phosphorylation of the unstable
intermediate, carbamate. This structural analysis reveals, for the
first time, the detailed manner in which CPS accommodates nucleotide
monophosphate effector molecules within the allosteric domain.
![]()
INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS AND DISCUSSION
REFERENCES
,
-heterodimer into an
(
,
)4-tetrameric species (1). The remaining domain (Ser937-Lys1073) has been shown by both x-ray
crystallographic and biochemical methods to harbor the binding sites
for such allosteric effectors as ornithine, UMP, and IMP.

View larger version (78K):
[in a new window]
Fig. 1.
Space-filling representation of the CPS
,
-heterodimer. The
N-terminal and C-terminal domains of the small subunit are color coded
in magenta and purple, respectively.
Met1 to Glu403, Val404 to
Ala553, Asn554 to Asn936, and
Ser937 to Lys1073 of the large subunit are
displayed in green, yellow, blue, and
red, respectively.
-amino group of this compound was shown to lie within hydrogen
bonding distance to O
of Tyr1040 in the
allosteric domain, whereas the
-amino group was positioned within
3.0 Å from the carboxylate groups of Glu783 and
Glu892, and O of Asp791, all of which originate
from the carbamoyl phosphate synthetic component. In addition, the
carboxylate group of ornithine was observed interacting with both the
backbone amide nitrogen and O
of Thr1042.
This same structure of CPS also provided the first hint for the
locations of the nucleotide monophosphate binding sites. Indeed, within
the allosteric domain, an inorganic phosphate was observed, hydrogen
bonded, and ion-paired to Lys954, Thr974,
Thr977, and Lys993. The hydroxyl group of
Thr977 had previously been
shown to be critical for the display of
the allosteric properties of UMP (11),
although somewhat later Lys993 was shown to be the residue
modified upon photolabeling CPS with UMP (12). From the above mentioned
data, a structural model was subsequently proposed by Thoden et
al. (1) for the binding of UMP or IMP to the allosteric domain of
the large subunit.
Intensity Statistics
Least squares refinement statistics
Relative to UMP, the allosteric properties exhibited by IMP are rather modest. Originally, IMP was described as an activator of CPS (13-15) but Reinhart and colleagues (7) elegantly demonstrated that the net allosteric effects of IMP can be modulated by temperature. At high temperatures, IMP activates CPS, whereas at lower temperatures the enzymatic activity is depressed. From past investigations (13, 14, 16), it was suggested that both IMP and UMP compete for the same binding site. More recently, it has been demonstrated quantitatively that the allosteric effects exhibited by IMP and UMP are strictly competitive with one another (17). These results are fully consistent with a common binding site for these two nucleotide monophosphate molecules. In contrast, ornithine and either IMP or UMP can bind simultaneously to CPS but the activation properties of ornithine completely dominate the inhibitory effects of either IMP or UMP (17).
Here we report the first structural analysis of the nucleotide
monophosphate allosteric binding site for CPS from E. coli. For this investigation, CPS was crystallized in the presence of both
IMP and ornithine. The IMP binding site was found to be contained wholly within the allosteric domain of CPS in a position consistent with previous biochemical data. The model presented here provides one
snapshot along the way toward a more complete structural understanding of the allosteric behavior displayed by this remarkable enzyme.
| |
EXPERIMENTAL PROCEDURES |
|---|
|
|
|---|
Purification and Crystallization Procedures--
Protein
employed in this investigation was purified as described previously
(18). For crystallization trials, the protein was concentrated to 4 mg/ml in 10 mM HEPES (pH 7.0) and 100 mM KCl.
Large single crystals were grown at 4 °C using a precipitant solution containing 0.65 M tetraethylammonium chloride, 8%
w/v (polyethylene) glycol 8000, 100 mM KCl, 0.5 mM MnCl2, 0.5 mM ornithine, 1.25 mM ADP, 1.25 mM BeF3, 5.0 mM IMP, and 25 mM HEPES (pH 7.4). The crystals
took approximately 3 months to achieve maximum dimensions of 1.2 × 0.5 × 0.4 mm. As in previous structural analyses of CPS from
E. coli, these crystals belonged to the space group
P212121 with unit cell dimensions
of a = 152.1 Å, b = 163.9 Å, and
c = 331.2 Å and one
(
,
)4-heterotetramer per asymmetric unit.
X-ray Data Collection and Processing--
Before x-ray data
collection, the crystals were transferred to a cryoprotectant solution
as described previously and subsequently flash-cooled to
150 °C in
a stream of nitrogen gas (2). X-ray data to 2.1 Å resolution were
collected at the Stanford Synchrotron Radiation Laboratory on beam-line
7-1 with the MAR300 image plate system. A low resolution x-ray data
set, consisting of eighty "1o" frames with the direct
beam centered on the detector and a crystal-to-detector distance of 420 mm, was collected first. These frames were collected with a constant
number of photons per frame. The detector was then translated up into
its offset position, again at a crystal-to-detector distance of 420 mm.
A total of 320 "0.7o" frames was collected. These
frames were processed with DENZO and scaled with SCALEPACK (19). From
3,249,722 measurements, 1,855,323 reflections were integrated and
reduced to 445,013 unique reflections after scaling. Scaling statistics
are presented in Table I.
The structure of the CPS·IMP complex described here was solved by the
technique of molecular replacement (20) with the software package AMORE
(21) and using, as a search model, the complete tetrameric form of CPS
previously refined to 2.1 Å resolution (2). Following rigid body
refinement, the model was subjected to least squares refinement at 2.1 Å resolution with the software package TNT (22). Because there were
over 5,800 amino acid residues in the asymmetric unit, the model
building and refinement processes were expedited by averaging the
electron densities corresponding to the four
,
-heterodimers in
the asymmetric unit as described previously (23). Alternate cycles of
rebuilding using this averaged electron density map followed by least
squares refinement of the "averaged" model expanded back into the
unit cell reduced the Rcryst to 20.8% and the
Rfree to 26.5%. For calculation of
Rfree, 5% of the x-ray data were removed from
the reflection file. At this point the entire tetrameric model was
adjusted in the unit cell and an additional cycle of least squares
refinement conducted leading to an Rcryst of
19.2% and an Rfree of 25.7%. A final cycle of
refinement was conducted with all measured x-ray data from 30 to 2.1 Å resulting in an R-factor of 19.3%. Relevant refinement statistics are presented in Table II. The CPS·IMP model described here includes eight ADP molecules, 12 manganese ions, 8 ornithines, 4 inorganic phosphates, 28 potassium ions, 12 chloride ions, 4,037 water
molecules, 4 tetraethylammonium ions, and 4 IMP molecules. The
following side chains were modeled as multiple conformations: Ser29, Arg130, Glu278,
Asp416, Glu655, Glu910,
Gln967, and Glu983 in the large subunit and
Arg215 in the small subunit of
,
-heterodimer I;
Arg145 in the large subunit and Met286 in the
small subunit of
,
-heterodimer II; Arg82,
Arg222, Arg490, Arg559,
Glu591, Lys634, Gln645,
Arg652, Glu771, Lys941,
Glu1009, and Arg1021 in the large subunit and
Gln78 in the small subunit of
,
-heterodimer III and
Lys35 and Glu478 in the large subunit of
,
-heterodimer IV. In addition, Cys269 was modeled as
sulfenic acid for all four small subunits contained within the
asymmetric unit.
| |
RESULTS AND DISCUSSION |
|---|
|
|
|---|
The CPS crystals employed in this investigation contained a
complete (
,
)4-heterotetramer in the asymmetric unit.
Because the four (
,
)-heterodimers are strikingly similar,
however, the following discussion will refer only to
(
,
)-heterodimer II as deposited in the Brookhaven Protein Data
Bank. Shown in Fig. 2 is the electron
density corresponding to the IMP ligand. The nucleotide fits the
electron density best with the ribose in the
C2'-endo conformation. The purine ring adopts an
anti-orientation and is tilted by approximately 156o from
the plane of the ribose ring. This is in sharp contrast to those
conformations observed for the ADP moieties bound to CPS whereby the
bases are tilted by approximately 128o and the ribose rings
adopt C3'-endo puckers. All the nucleotide monophosphates contained within the crystallographic asymmetric unit
are very well ordered with the IMP bound to (
,
)-heterodimer II
having an average temperature factor of 30.5 Å2.
|
The allosteric domain of CPS (Ser937 to
Lys1073) is characterized by a five-stranded parallel
-sheet flanked on either side by two and three
-helices,
respectively. As can be seen in Fig. 2, the IMP ligand is situated at
the C-terminal end of this sheet and, indeed, is completely contained
within the allosteric domain as originally predicted (1). A close-up
view of the IMP binding pocket is displayed in Fig.
3a and a cartoon of potential
hydrogen bonds between the ligand and the protein is shown in Fig.
3b. As indicated by the gray spheres in Fig. 3a,
there are three water molecules located within a 5 Å sphere of the
purine nucleotide. One side of the hypoxanthine ring is packed against
a fairly hydrophobic pocket formed by Ile1001,
Val1028, and Ile1029. The only direct
electrostatic contact between the purine base and the protein occurs
between O-6 of the hypoxanthine ring and N of
Val994. A water molecule is located within 3.0 Å to N-1 of
the purine base. Both N
2 of Asn1015 and
O
of Thr1017 serve to anchor the 2'-OH group
of the ribose to the protein. The 3'-OH group of the ribose lies within
hydrogen bonding distance to O of Thr1016. All three
phosphoryl oxygens form direct hydrogen bonds with the protein via the
side chain functional groups of Lys954, Thr974,
Thr977, and Lys993 as indicated by the dashed
lines in Fig. 3b. In addition, the backbone amide groups of
Gly976 and Thr977 also lie within hydrogen
bonding distance to two of the phosphoryl oxygens. Approximately 90%
of the surface area for the nucleotide ligand is buried upon binding to
CPS as calculated with the program GRASP and employing a search radius
of 1.4 Å (24).
|
The original structure of CPS was solved in the presence of both
Mn2+ADP and ornithine to 2.8 Å resolution (1). In that
model, two ornithine binding sites per
,
-heterodimer were
identified. The first ornithine was shown to bridge the C-domain of the
carbamoyl phosphate synthetic component to the allosteric domain. The
second ornithine, along with an inorganic phosphate, was positioned at the C-terminal end of the
-sheet in the allosteric domain. At that
time, it was postulated that the combination of ornithine and inorganic
phosphate was most likely mimicking the mode of binding for such
nucleotide ligands as UMP and IMP. For the subsequent x-ray data
collection and analysis of the CPS model to 2.1 Å resolution, the
crystals were first soaked in a solution containing 25 mM glutamine in an attempt to label the active site of the small subunit.
Although the glutamine did not bind in the active site in this study,
it did, however, displace the ornithine from its binding pocket in the
allosteric domain (2).
A superposition of this ligand binding site, as observed in the refined
structure of CPS, onto the present CPS·IMP model is depicted in Fig.
4. The phosphoryl group of the nucleotide
occupies a nearly identical position to that observed for the inorganic phosphate. This phosphate binding region is positioned at the N-terminal region of an
-helix formed by Thr974 to
Gly982. It can thus be speculated that both hydrogen bonds
and electrostatic interactions with the positive end of the helix
dipole serve to promote binding of phosphate moieties to this region of
the allosteric domain. The only two side chains that adopt
significantly different conformations between the two models are
Ile1001 and Ile1029 where their dihedral angles
differ by approximately 120-130o. Other than these side
chains, the two CPS complexes are remarkably similar, such that 5,744 of their backbone atoms coincide with a root mean square deviation of
0.31 Å. Recently, Bueso et al. (25) demonstrated that IMP
bound to CPS can be photocrosslinked to the large subunit in very low
yield. The only amino acid residue labeled after photoirradiation was
shown to be His995. Site-directed mutagenesis of
His995 to an alanine residue had relatively little effect
on either the catalytic or regulatory properties of CPS. In the crystal structure of the CPS·IMP complex reported here, the imidazole ring of
His995 is approximately 4 Å from the hypoxanthine ring of
the nucleotide monophosphate. The biochemical results of Bueso et
al. (25) are thus entirely consistent with the fact that
His995 does not significantly contribute to the binding
site for IMP.
|
In CPS, the IMP ligand binds to the C-terminal portion of a parallel
-sheet. A search of the Brookhaven Protein Data Bank reveals that
other enzymes have been solved in the presence of IMP, or analogs
thereof, including adenoylsuccinate synthetase (26). Detailed x-ray
crystallographic analyses of this enzyme have demonstrated that the IMP
ribose adopts the C2'-endo pucker with the
purine base oriented similarly to that observed in CPS (26).
Additionally, the phosphoryl group of the nucleotide is positioned
within approximately 5 Å of the N-terminal end of an
-helix formed
by Gly132 to Ala142. The IMP moiety is deeply
buried within the protein such that only about 1% of its surface area
is exposed to the solvent. Unlike that observed in CPS, the purine ring
makes numerous hydrogen bonding contacts with the protein. Note that
adenoylsuccinate synthetase catalyzes the production of
adenoylsuccinate from IMP, aspartate, and GTP, and in this case, the
nucleotide monophosphate is a true substrate. With regard to the role
of IMP acting solely as an effector molecule, however, the only other
observed structural example of IMP binding within an allosteric pocket
is that of glycogen phosphorylase (27). In this enzyme, the ribose of
the nucleotide adopts the C3'-endo pucker. The
ligand is positioned in a rather open region of the molecule with
approximately 48% of its surface area exposed to the solvent, the
hypoxanthine ring facing outwards and no direct protein contacts to the
base. Other than the similarities in ribose puckers between CPS and
adenoylsuccinate synthetase, the tertiary motifs employed for IMP
binding in these three enzymes are quite different.
The overall spatial relationships between the active sites of the small
and large subunits of CPS and the IMP and ornithine effector binding
pockets are depicted in Fig. 5. The
ornithine and IMP binding sites are separated by approximately 12 Å,
whereas the ornithine binding region and active site in the carbamoyl phosphate synthetic component are situated approximately 14 Å apart.
Previously, it was demonstrated that allosteric ligands such as IMP and
ornithine affect the carbamoyl phosphate-dependent ATP
synthesis reaction more so than the other two partial reactions catalyzed by CPS (7). The manner in which the IMP allosteric effector
site communicates to this Mg2+ATP binding site is most
likely via a complicated series of hydrogen bonds. As an example, there
is a hydrogen bonding pathway leading directly from the 2'-hydroxyl
group of the IMP ribose to one of the phosphoryl oxygens of the
Mn2+ADP. This hydrogen bonding network initiates via the
interaction between N
2 of Asn1015 and the
2'-hydroxyl group of IMP (Fig. 3b). The backbone amide group
of Asn1015 interacts with O of Asp1041. In this
region, O
of Thr1042 forms a hydrogen bond
with the carboxylate group of ornithine. In turn, the
-amino group
of ornithine lies within hydrogen bonding distance to O of
Asp791, whereas the backbone amide group of
Asp791 interacts with O of His788. Finally, the
imidazole side chain of His788 hydrogen bonds to a
phosphoryl oxygen of the Mn2+ADP moiety. Examination of the
CPS·IMP complex model described in this report demonstrates that
additional hydrogen bonding networks may also exist between the IMP
binding pocket and the active site of the carbamoyl phosphate synthetic
component.
|
From previous biochemical studies (13, 14, 16), it is known that IMP
and UMP compete for the same binding site on CPS. It can thus be
speculated that the structure of CPS described here reveals not only
the manner in which IMP is accommodated on the enzyme but also the mode
of UMP binding to the allosteric domain, at least as far as the
phosphoryl and sugar moieties are concerned. Recent detailed kinetic
analyses of the behavior of CPS in the presence of IMP, UMP, or
ornithine or combinations thereof have revealed a quite complicated set
of catalytic behaviors (17). In addition, these studies have
demonstrated that though both ornithine, an activator, and UMP, an
inhibitor, can bind simultaneously to CPS, the activating effect of
ornithine on the catalytic activity of CPS clearly prevails. What is
not apparent from the present structural studies is the manner in which
the enzyme discriminates between UMP and IMP. It would appear likely that the same molecular contacts are made to the ribose-phosphate moieties of UMP and IMP in the bound complexes. However, in the structure of IMP complexed to CPS, relatively few contacts are made to
the hypoxanthine ring system. We anticipate that a significant molecular rearrangement occurs upon the binding of UMP to CPS that is
not observed in the present model. These structural manifestations can
only be elucidated via a combination of biochemical and x-ray crystallographic experiments and, indeed, these investigations are in progress.
| |
ACKNOWLEDGEMENT |
|---|
We thank Dr. W. W. Cleland for helpful discussions. The high resolution x-ray data set employed in this structural analysis was collected at the Stanford Synchrotron Radiation Laboratory, which is funded by the Department of Energy, Office of Basic Energy Sciences.
| |
FOOTNOTES |
|---|
* This research was supported in part by Grants from the National Institutes of Health GM55513 (to H. M. H.) and DK30343 (to F. M. R.) and the National Science Foundation (BIR-9317398 shared instrumentation grant).The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
The atomic coordinates and structure factors (code 1CE8) have been deposited in the Protein Data Bank, Research Collaboratory for Structural Bioinformatics, Rutgers University, New Brunswick, NJ (http://www.rcsb.orgl).
¶ To whom correspondence should be addressed: Dept. of Biochemistry, College of Agricultural and Life Sciences, University of Wisconsin, Madison, 1710 University Ave., Madison, WI 53705. Tel.: 608-262-4988; Fax: 608-262-1319; E-mail: HOLDEN@ENZYME.WISC.EDU.
| |
ABBREVIATIONS |
|---|
The abbreviation used is: CPS, carbamoyl phosphate synthetase.
| |
REFERENCES |
|---|
|
|
|---|
| 1. | Thoden, J. B., Holden, H. M., Wesenberg, G., Raushel, F. M., and Rayment, I. (1997) Biochemistry 36, 6305-6316[CrossRef][Medline] [Order article via Infotrieve] |
| 2. | Thoden, J. B., Raushel, F. M., Benning, M. M., Rayment, I., and Holden, H. M. (1999) Acta Crystallogr. Sec. D. 55, 8-24[CrossRef][Medline] [Order article via Infotrieve] |
| 3. | Schirmer, T., and Evans, P. R. (1990) Nature 343, 140-145[CrossRef][Medline] [Order article via Infotrieve], and references therein |
| 4. | Kosman, R. P., Gouaux, J. E., and Lipscomb, W. N. (1993) Proteins Struct. Funct. Genet. 15, 147-176, and references therein [CrossRef][Medline] [Order article via Infotrieve] |
| 5. | Liaw, S. H., Jun, G., and Eisenberg, D. (1994) Biochemistry 33, 11184-11188[CrossRef][Medline] [Order article via Infotrieve], and references therein |
| 6. | Gregoriou, M., Noble, M. E., Watson, K. A., Garman, E. F., Krulle, T. M., de la Fuente, C., Fleet, G. W., Oikonomakos, N G., and Johnson, L. N. (1998) Protein Sci. 7, 915-927[Abstract], and references therein |
| 7. | Braxton, B. L., Mullins, L. S., Raushel, F. M., and Reinhart, G. D. (1992) Biochemistry 31, 2309-2316[CrossRef][Medline] [Order article via Infotrieve] |
| 8. | Braxton, B. L., Mullins, L. S., Raushel, F. M., and Reinhart, G. D. (1996) Biochemistry 35, 11918-11924[CrossRef][Medline] [Order article via Infotrieve] |
| 9. | Matthews, S. L., and Anderson, P. M. (1972) Biochemistry 11, 1176-1183[CrossRef][Medline] [Order article via Infotrieve] |
| 10. |
Trotta, P. P.,
Burt, M. E.,
Haschemeyer, R. H.,
and Meister, A.
(1971)
Proc. Natl. Acad. Sci. U. S. A.
68,
2599-2603 |
| 11. | Czerwinski, R. M., Mareya, S. M., and Raushel, F. M. (1995) Biochemistry 34, 13920-13927[CrossRef][Medline] [Order article via Infotrieve] |
| 12. | Cervera, J., Bendala, E., Britton, H. G., Bueso, J., Nassif, Z., Lusty, C. J., and Rubio, V. (1996) Biochemistry 35, 7247-7255[CrossRef][Medline] [Order article via Infotrieve] |
| 13. |
Boettcher, B.,
and Meister, A.
(1981)
J. Biol. Chem.
256,
5977-5980 |
| 14. |
Boettcher, B.,
and Meister, A.
(1982)
J. Biol. Chem.
257,
13971-13976 |
| 15. | Kasprzak, A. A., and Villafranca, J. J. (1988) Biochemistry 27, 8050-8056[CrossRef][Medline] [Order article via Infotrieve] |
| 16. | Anderson, P. M. (1977) Biochemistry 16, 587-593[CrossRef][Medline] [Order article via Infotrieve] |
| 17. | Braxton, B. L., Mullins, L. S., Raushel, F. M., and Reinhart, G. D. (1999) Biochemistry 38, 1394-1401[CrossRef][Medline] [Order article via Infotrieve] |
| 18. | Miran, S. G., Chang, S. H., and Raushel, F. M. (1991) Biochemistry 30, 7901-7907[CrossRef][Medline] [Order article via Infotrieve] |
| 19. | Otwinowski, Z. (1993) in Proceedings of the CCP4 Study Weekend: Data Collection and Processing, Oscillation Data Reduction Program (Sawyer, L. , Isaacs, N. , and Bailey, S., eds) , pp. 56-62, SERC Daresbury Laboratory, United Kingdom |
| 20. | Rossmann, M. G. (1972) The Molecular Replacement Method , Gordon and Breach Science Publishers, Inc., New York |
| 21. | Navaza, J. (1994) Acta Crystallogr. Sec. A 50, 157-163[CrossRef] |
| 22. | Tronrud, D. E., Ten Eyck, L. F., and Matthews, B. W. (1987) Acta Crystallogr. Sect. A 43, 489-501[CrossRef] |
| 23. | Thoden, J. B., Miran, S. G., Phillips, J. C., Howard, A. J., Raushel, F. M., and Holden, H. M. (1998) Biochemistry 37, 8825-8831[CrossRef][Medline] [Order article via Infotrieve] |
| 24. | Nicholls, A., Sharp, K. A., and Honig, B. (1991) Proteins Struct. Funct. Genet. 11, 281-296 [CrossRef][Medline] [Order article via Infotrieve] |
| 25. | Bueso, J., Cervera, J., Fresquet, V., Marina, A., Lusty, C. J., and Rubio, V. (1999) Biochemistry 38, 3910-3917[CrossRef][Medline] [Order article via Infotrieve] |
| 26. | Poland, B. W., Fromm, H. J., and Honzatko, R. B. (1996) J. Mol. Biol. 264, 1013-1027[CrossRef][Medline] [Order article via Infotrieve] |
| 27. | Oikonomakos, N. G., Zographos, S. E., Tsitsanou, K. E., Johnson, L. N., and Acharya, K. R. (1996) Protein Sci. 5, 2416-2428[Abstract] |
This article has been cited by other articles:
![]() |
J. B. Thoden, X. Huang, J. Kim, F. M. Raushel, and H. M. Holden Long-range allosteric transitions in carbamoyl phosphate synthetase Protein Sci., September 1, 2004; 13(9): 2398 - 2405. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. Eroglu and S. G. Powers-Lee Unmasking a Functional Allosteric Domain in an Allosterically Nonresponsive Carbamoyl-phosphate Synthetase J. Biol. Chem., November 15, 2002; 277(47): 45466 - 45472. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. B. Thoden, X. Huang, F. M. Raushel, and H. M. Holden Carbamoyl-phosphate Synthetase. CREATION OF AN ESCAPE ROUTE FOR AMMONIA J. Biol. Chem., October 11, 2002; 277(42): 39722 - 39727. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Saeed-Kothe and S. G. Powers-Lee Specificity Determining Residues in Ammonia- and Glutamine-dependent Carbamoyl Phosphate Synthetases J. Biol. Chem., February 22, 2002; 277(9): 7231 - 7238. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Ahuja, C. Purcarea, H. I. Guy, and D. R. Evans A Novel Carbamoyl-Phosphate Synthetase from Aquifex aeolicus J. Biol. Chem., November 30, 2001; 276(49): 45694 - 45703. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| All ASBMB Journals | Molecular and Cellular Proteomics |
| Journal of Lipid Research | ASBMB Today |